EFM
STOK icon

E Fund Management’s Stoke Therapeutics STOK Stock Holding History

E Fund Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Sell
6,168
-1,362
-18% -$43.7K ﹤0.01% 454
2026
Q1 		$245K Buy
+7,530
New +$247K 0.01% 423

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

E Fund Management's STOK Position: Q2 2026 in Review

E Fund Management reduced its Stoke Therapeutics (STOK) stake by 18% in Q2 2026, selling an estimated $43.7K and leaving 6,168 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #454.

E Fund Management first reported a position in STOK in Q1 2026 and has held it in 2 quarters since. The position peaked at $245K in Q1 2026. 198 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • E Fund Management held 6,168 shares of Stoke Therapeutics worth $202K as of Q2 2026.
  • E Fund Management sold 1,362 Stoke Therapeutics shares in Q2 2026, an estimated $43.7K.
  • Stoke Therapeutics made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #454 holding.
  • E Fund Management first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • E Fund Management's Stoke Therapeutics position peaked at $245K in Q1 2026.
  • 198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.